search
Back to results

Tenelia Triple Combination Study (TETRIS)

Primary Purpose

Type 2 Diabetes Mellitus

Status
Completed
Phase
Phase 3
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Teneligliptin
Sponsored by
Handok Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes Mellitus

Eligibility Criteria

19 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Patients with Type 2 Diabetes Mellitus
  2. Adults aged ≥ 19 years old
  3. Patients with HbA1c 7%~11% at Screening and Run-in visit

Exclusion Criteria:

-

Sites / Locations

  • Samsung Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Teneligliptin

Sitagliptin

Arm Description

20mg qd

100mg qd

Outcomes

Primary Outcome Measures

Change of HbAlc from baseline at Week 24

Secondary Outcome Measures

Full Information

First Posted
October 2, 2015
Last Updated
April 30, 2018
Sponsor
Handok Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT02567994
Brief Title
Tenelia Triple Combination Study
Acronym
TETRIS
Official Title
Efficacy and Safety of Teneligliptin Versus Sitagliptin as add-on Therapy to Metformin Plus Glimepiride in T2DM Patinets With Inadequate Glycemic Control
Study Type
Interventional

2. Study Status

Record Verification Date
April 2018
Overall Recruitment Status
Completed
Study Start Date
April 2015 (Actual)
Primary Completion Date
October 2017 (Actual)
Study Completion Date
December 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Handok Inc.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
After a screening, a 2-week, single-blind placebo run-in, 200 patients will be randomized in a 1 : 1 ratio to the addition of either once-daily Teneligliptin 20mg or sitagliptin 100mg to ongoing stable doses of glimepiride in combination with metformin for 24 weeks.
Detailed Description
Subjects will visit the centers on Week 4, 12 and 24 during the entire 24-week treatment period. Total study duration will be approximately 28weeks and the subjects will be to practice exercise/diet control together.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
201 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Teneligliptin
Arm Type
Experimental
Arm Description
20mg qd
Arm Title
Sitagliptin
Arm Type
Active Comparator
Arm Description
100mg qd
Intervention Type
Drug
Intervention Name(s)
Teneligliptin
Intervention Description
Subjects will visit the center on Week 4, 12 and 24 during the entire 24-week treatment period. Total study duration will be approximately 28weeks and the subjects will be to practice exercise/diet control together.
Primary Outcome Measure Information:
Title
Change of HbAlc from baseline at Week 24
Time Frame
24 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
19 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with Type 2 Diabetes Mellitus Adults aged ≥ 19 years old Patients with HbA1c 7%~11% at Screening and Run-in visit Exclusion Criteria: -
Facility Information:
Facility Name
Samsung Medical Center
City
Seoul
Country
Korea, Republic of

12. IPD Sharing Statement

Plan to Share IPD
Yes

Learn more about this trial

Tenelia Triple Combination Study

We'll reach out to this number within 24 hrs